Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance - 24/10/24
, Celine I Mandara, PhD a, Catherine Bakari, MSc a, Abebe A Fola, PhD c, d, Rashid A Madebe, MSc a, Misago D Seth, PhD a, Filbert Francis, PhD a, Creyton C Buguzi, MD a, Ramadhan Moshi, BSc a, Issa Garimo, MPH e, Samwel Lazaro, MPH e, Abdallah Lusasi, MPH e, Sijenunu Aaron, MSc e, Frank Chacky, MSc e, Ally Mohamed, MPH e, Ritha J A Njau, PhD f, Jovin Kitau, PhD g, Charlotte Rasmussen, PhD h, Jeffrey A Bailey, PhD c, d, †, Jonathan J Juliano, ProfMD i, †, Marian Warsame, PhD j, k, †Summary |
Background |
In 2021, nationwide malaria molecular surveillance revealed a high prevalence of a validated artemisinin resistance marker, the kelch13 (k13) Arg561His mutation, in the Kagera region of northwestern Tanzania. We aimed to investigate the efficacy of artemether–lumefantrine and artesunate–amodiaquine and to confirm the presence of artemisinin partial resistance (ART-R) in the Karagwe district of this region.
Methods |
This single-arm, therapeutic efficacy study was carried out at the Bukangara dispensary in the Karagwe district of the Kagera region in northwestern Tanzania. Eligible participants were aged between 6 months and 120 months, had confirmed Plasmodium falciparum asexual parasitaemia, and met other inclusion criteria according to WHO’s standard protocol. Participants were enrolled, treated sequentially with either artemether–lumefantrine or artesunate–amodiaquine, and assessed clinically and parasitologically for 28 days as per WHO protocol. Parasitaemia was measured every 8 h until day 3, on day 7, and then during weekly follow-up visits until day 28. Mutations in the k13 gene and extended haplotypes with the mutations were analysed, and comparisons were made with previous samples collected in the same region of Kagera and in Rwanda and southeast Asia. The primary endpoint was PCR-corrected cure rate.
Findings |
Between April 29 and Sept 1, 2022, 343 patients were screened, of whom 176 were enrolled: 88 in each treatment group. The PCR-corrected cure rate was 98% (95% CI 91–100) in the artemether–lumefantrine group and 100% (96–100) in the artesunate–amodiaquine group. Persistent parasitaemia on day 3 occurred in 11 (13%) of 88 patients in the artemether–lumefantrine group and 17 (19%) of 88 patients in the artesunate–amodiaquine group. Arg561His mutations on day 0 and parasitaemia on day 3 were reported in eight (9%) of 87 patients in the artemether–lumefantrine group and ten (12%) of 86 patients in the artesunate–amodiaquine group. The median parasite clearance half-life in patients harbouring parasites with Arg561His mutation was 6·1 h in the artemether–lumefantrine group and 6·0 h in the artesunate–amodiaquine group. Parasites with the Arg561His mutation were not similar to those from southeast Asia and Rwanda but had similar haplotypes to parasites reported in the same Tanzanian region of Kagera in 2021.
Interpretation |
This study confirms the presence of ART-R in Tanzania, although artemether–lumefantrine and artesunate–amodiaquine showed high efficacy. A context-specific response strategy and vigilance to detect the reduced efficacy of current antimalarial treatments and ART-R in other parts of the country are urgently needed.
Funding |
The Bill & Melinda Gates Foundation and the US National Institutes of Health.
Le texte complet de cet article est disponible en PDF.Plan
Vol 24 - N° 11
P. 1225-1233 - novembre 2024 Retour au numéro
Article précédent
- Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study
- Ming Hong Choi, Eric Yuk Fai Wan, Ian Chi Kei Wong, Esther Wai Yin Chan, Wing Ming Chu, Anthony Raymond Tam, Kwok Yung Yuen, Ivan Fan Ngai Hung
- Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil
- Mauricio L Nogueira, Monica A T Cintra, José A Moreira, Elizabeth G Patiño, Patricia Emilia Braga, Juliana C V Tenório, Lucas Bassolli de Oliveira Alves, Vanessa Infante, Daniela Haydee Ramos Silveira, Marcus Vínicius Guimarães de Lacerda, Dhelio Batista Pereira, Allex Jardim da Fonseca, Ricardo Queiroz Gurgel, Ivo Castelo-Branco Coelho, Cor Jesus Fernandes Fontes, Ernesto T A Marques, Gustavo Adolfo Sierra Romero, Mauro Martins Teixeira, André M Siqueira, Viviane Sampaio Boaventura, Fabiano Ramos, Erivaldo Elias Júnior, José Cassio de Moraes, Stephen S Whitehead, Alejandra Esteves-Jaramillo, Tulin Shekar, Jung-Jin Lee, Julieta Macey, Sabrina Gozlan Kelner, Beth-Ann G Coller, Fernanda Castro Boulos, Esper G Kallás, Phase 3 Butantan-DV Working Group, Wuelton Monteiro, Joabi Nascimento, Rosilene Ruffato, Eduardo Garbin, Érica Cristina da Silva, Solange Cunha da Silva, Anna Paula Ioris, Antonia Francileuda Casarin, Volfânio Andrade, Vitor Menezes, Flávio Henrique Dourado de Macêdo, Guilherme Alves de Lima Henn, Andréa de Almeida Coêlho, Luciano Teixeira Gomes, Tiago Rodrigues Viana, Pedro de Carvalho Ferreira, Ana Maria Aguiar dos Santos, Irassandra Rooze Pereira Uchôa Cavalcanti de Aquino, Rafael Dhalia, Karla Andreia Mëtte Waldrich Tauil, Valéria Gonçalves Santos, Camilla dos Santos Mota, Helton Santiago, Lisia Esper, Ultimo Libanio, Cassia Fernanda Estofolete, Samuel Noah Scamardi, Paula Patrícia de Freitas Chama, Barbara Azevedo, Clarisse Bressan, Patricia Brasil, Aldina Barral, Antonio Bandeira, Daniela Paixão, Angela Carvalho Freitas, Pedro Henrique Fernandes Moreira de Figueiredo, Luara Teófilo Pignati, Cristina Bonorino, Larissa Sanches, Isabelli Guasso, Vanessa Terezinha Gubert, Jéssica Melo Silva da Silveira, Christiane Herold de Jesus, Sonia Regina de Almeida, Maria do Carmo Sampaio Tavares Timenetsky, Cecilia Luisa Simões Santos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?